Literature DB >> 1996970

Low-Mr heparin is as potent as conventional heparin in releasing lipoprotein lipase, but is less effective in preventing hepatic clearance of the enzyme.

G Q Liu1, G Bengtsson-Olivecrona, P Ostergaard, T Olivecrona.   

Abstract

This study compares a low-Mr heparin preparation with conventional heparin with respect to its interaction with lipoprotein lipase (LPL) in vitro and its effects on the enzyme in vivo. Both heparin preparations were polydisperse in binding to LPL, but on average the low-Mr preparation showed lower affinity. Thus both conventional and low-Mr heparin bound quantitatively to immobilized LPL, and were eluted as broad peaks when a salt gradient was applied, but the peak for low-Mr heparin was shifted towards lower salt concentrations. To displace LPL from immobilized heparin a higher concentration of low-Mr than of conventional heparin was needed. Injection of the low-Mr heparin into intact rats resulted in lower plasma LPL activity than did injection of an equal mass of conventional heparin, but when the liver was excluded from the circulation both heparin preparations resulted in similar plasma LPL activities. In perfused rat hearts, low-Mr heparin had at least the same effect on the release of LPL activity as did conventional heparin. In perfused livers, on the other hand, low-Mr heparin was less effective than conventional heparin in preventing the rapid uptake of exogenous labelled LPL. Hence the apparently lower average affinity of low-Mr heparin for LPL does not result in a demonstrably lower potency to release the enzyme from endothelial binding sites in peripheral tissues, but does result in a substantially decreased effect on the hepatic clearance of the enzyme.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1996970      PMCID: PMC1149826          DOI: 10.1042/bj2730747

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  27 in total

1.  THE ROLE OF SERINE IN THE LINKAGE OF HEPARIN TO PROTEIN.

Authors:  U LINDAHL; J A CIFONELLI; B LINDAHL; L RODEN
Journal:  J Biol Chem       Date:  1965-07       Impact factor: 5.157

2.  Pharmacokinetics of fragmin. A comparative study in the rabbit of its high and low affinity forms for antithrombin.

Authors:  M Palm; C Mattsson
Journal:  Thromb Res       Date:  1987-10-01       Impact factor: 3.944

3.  Relationship between biological activity and concentration of a low-molecular-weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration.

Authors:  J Dawes; L Bara; E Billaud; M Samama
Journal:  Haemostasis       Date:  1986

4.  Low molecular weight heparin (KABI 2165, Fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteers.

Authors:  G Bratt; E Törnebohm; L Widlund; D Lockner
Journal:  Thromb Res       Date:  1986-06-01       Impact factor: 3.944

5.  A simple and inexpensive membrane "lung" for small organ perfusion.

Authors:  R L Hamilton; M N Berry; M C Williams; E M Severinghaus
Journal:  J Lipid Res       Date:  1974-03       Impact factor: 5.922

6.  Effects of an enzymatically depolymerized heparin as compared with conventional heparin in healthy volunteers.

Authors:  T Mätzsch; D Bergqvist; U Hedner; P Ostergaard
Journal:  Thromb Haemost       Date:  1987-02-03       Impact factor: 5.249

7.  Anticoagulant and lipolytic effects of a low molecular weight heparin fraction.

Authors:  J Harenberg; A Gnasso; J X de Vries; R Zimmermann; J Augustin
Journal:  Thromb Res       Date:  1985-09-15       Impact factor: 3.944

8.  Metabolic fate of rat heart endothelial lipoprotein lipase.

Authors:  T Chajek-Shaul; G Bengtsson-Olivecrona; J Peterson; T Olivecrona
Journal:  Am J Physiol       Date:  1988-09

9.  Lipoprotein lipase uptake by the liver: localization, turnover, and metabolic role.

Authors:  S Vilaró; M Llobera; G Bengtsson-Olivecrona; T Olivecrona
Journal:  Am J Physiol       Date:  1988-05

10.  Plasma kinetics of lipoprotein lipase and hepatic lipase activities induced by heparin and a low molecular weight heparin fragment.

Authors:  E Persson; J Nordenström; P Nilsson-Ehle
Journal:  Scand J Clin Lab Invest       Date:  1987-04       Impact factor: 1.713

View more
  8 in total

1.  Effect of protamine on lipoprotein lipase and hepatic lipase in rats.

Authors:  M Hultin; G Olivecrona; T Olivecrona
Journal:  Biochem J       Date:  1994-12-15       Impact factor: 3.857

2.  Domain structure of endothelial heparan sulphate.

Authors:  A Lindblom; G Bengtsson-Olivecrona; L A Fransson
Journal:  Biochem J       Date:  1991-11-01       Impact factor: 3.857

3.  Structure of heparin fragments with high affinity for lipoprotein lipase and inhibition of lipoprotein lipase binding to alpha 2-macroglobulin-receptor/low-density-lipoprotein-receptor-related protein by heparin fragments.

Authors:  A Larnkjaer; A Nykjaer; G Olivecrona; H Thøgersen; P B Ostergaard
Journal:  Biochem J       Date:  1995-04-01       Impact factor: 3.857

4.  Release of lipoprotein lipase from cardiac myocytes by low-molecular weight heparin.

Authors:  J E Braun; D L Severson
Journal:  Lipids       Date:  1993-01       Impact factor: 1.880

5.  Interaction of size-fractionated heparins with lipoprotein lipase and hepatic lipase in the rat.

Authors:  G Liu; M Hultin; P Ostergaard; T Olivecrona
Journal:  Biochem J       Date:  1992-08-01       Impact factor: 3.857

Review 6.  Tinzaparin sodium: a review of its pharmacology and clinical use in the prophylaxis and treatment of thromboembolic disease.

Authors:  Susan M Cheer; Christopher J Dunn; Rachel Foster
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 7.  Tinzaparin. A review of its pharmacology and clinical potential in the prevention and treatment of thromboembolic disorders.

Authors:  H A Friedel; J A Balfour
Journal:  Drugs       Date:  1994-10       Impact factor: 9.546

8.  Lipoprotein lipase in hemodialysis patients: indications that low molecular weight heparin depletes functional stores, despite low plasma levels of the enzyme.

Authors:  Birgit Näsström; Bernd Stegmayr; Gunilla Olivecrona; Thomas Olivecrona
Journal:  BMC Nephrol       Date:  2004-11-03       Impact factor: 2.388

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.